

# Limb-Girdle Muscular Dystrophies: *Clinical Course of Disease and Advances in Gene Therapy Development*

**Thursday, November 30, 2023**

**6:45–7:45 PM CET**

This program aims to review the current understanding and unmet needs of limb-girdle muscular dystrophies (LGMDs) as well as explore the rationale and clinical data for an investigational gene therapy for a particular LGMD subtype, LGMD2E/R4

## Speakers



**Dr. med. André Müller-York**  
Senior Director, LGMD Medical Lead,  
Global Medical Affairs  
Sarepta Therapeutics, Inc.



**Jesantha Coy, B Pharm**  
Executive Director,  
Global Program Team Leader  
Sarepta Therapeutics, Inc.

This presentation was approved by the Program Committee as an independent activity held in conjunction with ICNMDigital 2023. This presentation is not sponsored or endorsed by ICNMDigital 2023.

SAREPTA, SAREPTA THERAPEUTICS, and the SAREPTA Helix Logo are trademarks of Sarepta Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and may be registered in various other jurisdictions.



©2023 SAREPTA THERAPEUTICS. Copying of this material by any means without SAREPTA's prior written consent is prohibited. C-NP-GBL-0325 09/23